choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:

Orexigen Newsletter
  • LB-102: Redefining schizophrenia treatment in drug discovery 21 Apr 2025 07:53 GMT

    … in leading biotech companies to her … drug discovery in neuropsychiatric treatment The positive results from the trialmedication regimens.” This forward-thinking approach demonstrates LB Pharmaceuticals … HR, and medical affairs. At Orexigen Therapeutics, Inc …

  • Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla 31 Mar 2025 11:44 GMT

    … (ARIA) with the drug, like brain bleeding and … medicines, Averoa's Xoanacyl (ferric citrate coordination complex) for the treatment … formulation of blockbuster cancer drug Opdivo (nivolumab). Meanwhile, … of the safety of Orexigen's weight-loss …

  • EMA Recommends Five New Medicines for Approval 28 Mar 2025 21:17 GMT

    … Calquence (acalabrutinib), Flucelvax (influenza vaccine—surface antigen, inactivated, prepared … CHMP recommended a new pharmaceutical form as well as … seed), an herbal medicine for treatment of moderate-to- … a review of Orexigen Therapeutics Ireland’s Mysimba …

  • Anti-Obesity Drugs Market to Expand from USD 4.6 Billion in 2023 to USD 39.3 Billion by 2033 06 Feb 2025 07:52 GMT

    trial data collection. •Personalized Treatments: AI customizes obesity treatmentsbiotechnologymedications. The presence of major pharmaceutical companies ensures easy access to innovative drugs … •Orexigen Therapeutics, Inc. •Rhythm Pharmaceuticals, …

  • Determining the Correlation Between Obesity Management Drug Dispensed Prescriptions and Online Search Behavior 31 Jan 2025 04:39 GMT

    treatments of a healthy diet and exercise, the pharmaceutical … clinical trials have been demonstrating that this drug class … : FDA-approved OMDs (naltrexone and bupropion [Contrave; Orexigen Therapeutics … shift in obesity medication patterns, with semaglutide …

  • Increase in online searches for obesity drugs correlates with rise in prescriptions 29 Jan 2025 21:15 GMT

    … for FDA-approved medications for obesity and GLP-1-based drugs for diabetes … for naltrexone/bupropion (Contrave, Orexigen Therapeutics) from July 2022 through … prescribed off-label for obesity treatment,” the researchers wrote. “We considered …

  • Hims & Hers buys Zava to form European beachhead 04 Jun 2025 15:07 GMT

    … the supply of weight-loss medicines. The cash-based acquisition … range of weight-loss treatments available on an out- … tirzepatide), and older therapies like Orexigen's Mysimba (naltrexone … drugs were in limited supply. Now, with both products off the FDA

  • Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids 15 Nov 2024 16:03 GMT

    … ensure clearance of opioid medication before starting treatment with Mysimba. Patients must … the company that markets Mysimba, Orexigen Therapeutics Ireland Limited, to submit … a group of experts including doctors specialised in anaesthesiology, obesity and …

  • Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors 18 Nov 2024 21:05 GMT

    … Turner is a seasoned biotechnology executive with 25 years … Therapeutics, Atara Biotherapeutics, Orexigen Therapeutics, and Conor Medsystems … Barbara. About Terns Pharmaceuticals Terns Pharmaceuticals, Inc. is a … of the clinical trials and other development …

  • FDA Commissioner Shills for New Diet Drugs 17 Oct 2024 18:57 GMT

    … of us consult with the pharmaceutical industry, which I think … Califf presided over a discredited drug trial of the blood thinner Xarelto … to an experimental cancer treatment at Duke occurred while … medical journals and a great university." This is FDA

Satisfied with the content?

Continue to create your account.